Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas J. FeliuJ. García SáenzM. González Barón Original Article 11 January 2006 Pages: 419 - 426
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer Paul L. de SouzaWinston LiauwLaurence G. Howes Original Article 04 February 2006 Pages: 427 - 433
Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells Jun YuQing-Long GuoXiaotang Wang Original Article 10 February 2006 Pages: 434 - 443
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling Ryan WilliamsAmanda F. BakerGarth Powis Original Article 17 February 2006 Pages: 444 - 450
The tumor specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam Hironori IwasakiHirosuke OkuMasashi Inafuku Original Article 08 February 2006 Pages: 451 - 459
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells Junichi KurebayashiSumiko OkuboHiroshi Sonoo Original Article 25 January 2006 Pages: 460 - 470
Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins Tamer E. FandyRakesh K. Srivastava Original Article 25 January 2006 Pages: 471 - 477
Distribution of 5-aminolevulinic acid derivatives and induced porphyrin kinetics in mice tissues Gabriela Di VenosaAlcira BatlleAdriana Casas Original Article 17 February 2006 Pages: 478 - 486
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Søren Astrup JensenJens Benn Sørensen Original Article 18 January 2006 Pages: 487 - 493
Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea K. TakasunaT. HagiwaraT. Kamataki Original Article 25 January 2006 Pages: 494 - 503
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma Maurizio CantoreGiovanni SerioGiammaria Fiorentini Original Article 22 April 2006 Pages: 504 - 508
Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer J. R. KroepE. F. SmitG. J. Peters Original Article 07 March 2006 Pages: 509 - 516
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism B. J. CusackH. GamblielR. D. Olson Original Article 23 March 2006 Pages: 517 - 526
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer J. FeliuG. MartínM. Gonzalez-Barón Original Article 23 March 2006 Pages: 527 - 531
Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat Hong LuKenneth K. Chan Original Article 10 February 2006 Pages: 532 - 539
Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells Bo YangLingling FanQiaojun He Original Article 07 March 2006 Pages: 540 - 546
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells Lars Petter JordheimCarlos M. GalmariniCharles Dumontet Original Article 04 February 2006 Pages: 547 - 554
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial G. P. StathopoulosC. KatisE. Dimou Original Article 07 March 2006 Pages: 555 - 560